26.11.2014 Views

The YBM Magnex Files Adrian du Plessis ... - Deep Capture

The YBM Magnex Files Adrian du Plessis ... - Deep Capture

The YBM Magnex Files Adrian du Plessis ... - Deep Capture

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Proposing a corporate name change to US Biogenix, the new President Skillern explained:<br />

?<strong>The</strong> original name reflected the use of cryopreservation in our proposed pregnancy suspension<br />

technology, but unfortunately the social, ideological and political opponents made it impossible<br />

to deliver that service so we redirected our efforts toward telomere biology and its applications<br />

to aging, cancer and other therapies.?<br />

A cure for cancer may be a goal sufficient for some to achieve, but CYGS saw wider benefits to<br />

be realized from ?optimizing the value of the TeloVector ? in all its manifestations.? This<br />

technology, it was stated, was expected to have application to the shrimp farming in<strong>du</strong>stry and<br />

the company reported it would ?spin off (its) aquaculture division into a separate corporation.?<br />

CYGS director of research Craig Tomlinson, PhD, said, ?We believe we can grow more shrimp,<br />

faster and larger, and pro<strong>du</strong>ce a ?clean? shrimp, free of environmental or viral contaminants.?<br />

Cancer cures and bigger, healthier, shrimp promised by a OTC stock venture trading for dimes<br />

and promoted by an S&M advocate may not raise too many eyebrows in today?s investment<br />

climate, but Cryogenic?s other press release of January 5 1998 did cause some dissonance in<br />

financial chat circles on-line.<br />

CYGS announced that it had agreed to license its TeleVector ? technology to something called<br />

Clinica Lirpa, S.A. of Costa Rica. According to Mike Skillern, ?Clinica Lirpa, S.A. is especially<br />

interested in the gerontology (anti-aging) and oncology (anti-cancer) applications of the<br />

TeloVector.? Such an arrangement with an obscure Central American entity is not that out-ofthe-ordinary<br />

for a typically surreal junior public company.<br />

(I recall investigating one Canadian public company, Technigen Corp., that claimed to be selling<br />

over CDN $100 million worth of computerized golf driving ranges to Corporacion Relacio, S.A. -<br />

purportedly a Swiss company. Even though it was documented that Relacio, S.A. was, in fact, a<br />

Panamanian-registered shell whose signing representative in Canada was an ex-convict stock<br />

swindler who?d been banned for life from the Vancouver Stock Exchange, VSE officials were<br />

satisfied. Coincidentally, a founding Technigen shareholder, and its subsequent head of<br />

Investor Relations, Michael Schmidt, was one of the founding directors of Pratecs/<strong>YBM</strong>.)<br />

What drew the disdain of several internet stock-watchers was the company?s declaration: ?As a<br />

condition of the license agreement, Clinica Lirpa has agreed to ?preferential access? for anyone<br />

owning 5,000 or more shares of (Cryogenic Solutions) common stock as of March 1, 1998.<br />

?Essentially, Clinica Lirpa will confirm reservations to qualified indivi<strong>du</strong>als with at least 5,000<br />

shares registered in their name,? said Skillern. ?Everyone else will be served on a space<br />

available basis. This preferential service access will be for all services offered by Clinica Lirpa,<br />

not just services developed from our TeleVector ? ?.?<br />

When Silicon Investor posters reacted by calling this news ?spooky and unethical?,<br />

?PREJUDICIAL? and ?completely bizarro? one of a tag-team of on-line boosters, Barry R.,<br />

jumped to the defense of CYGS: ?Overall I think it?s a great idea to make patients part owners

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!